Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease.

Andrew L SchmidtAngelyn AntonJulia ShapiroShirley WongArun AzadEdmond KwanLavinia SpainArun MuthusamyJavier TorresPhillip ParenteFrancis ParnisJeffrey GohAnthony M JoshuaDavid PookPeter GibbsBen TranAndrew Weickhardt

Published in: Asia-Pacific journal of clinical oncology (2020)

Abiraterone, enzalutamide, cabazitaxel and docetaxel all demonstrate activity following progression on D-ADT. No difference in efficacy was detected between treatment options for mCRPC. Prospective trials investigating the optimal treatment sequence for prostate cancer following progression on D-ADT needed.

Keyphrases

prostate cancer
radical prostatectomy
locally advanced
rectal cancer
amino acid